Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 127Ovarian Neoplasms 79Fallopian Tube Neoplasms 45Lung Neoplasms 42Carcinoma, Ovarian Epithelial 30Uterine Cervical Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 27Endometrial Neoplasms 25Triple Negative Breast Neoplasms 23Neoplasm Metastasis 21Neoplasms 20Esophageal Neoplasms 19Stomach Neoplasms 18Esophageal Squamous Cell Carcinoma 15Adenocarcinoma of Lung 13Carcinoma 12Brenner Tumor 11Recurrence 10Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Peritoneal Neoplasms 7Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Melanoma 4Carcinoma, Ductal, Breast 4Adenocarcinoma Of Esophagus 4

Interventions

sintilimab 1Paclitaxel 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Diseases × Paclitaxel × Clear all
NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡